Immune Correlates Analysis of mRNA-1345 RSV Vaccine Efficacy Clinical Trial

NIAID Data Ecosystem2026-05-02 收录

数据链接：

https://figshare.com/articles/dataset/Immune_Correlates_Analysis_of_mRNA-1345_RSV_Vaccine_Efficacy_Clinical_Trial/29119217 数据链接链接失效反馈

官方服务：

资源简介：

Source data associated with the Immune Correlates Analysis of mRNA-1345 RSV Vaccine Efficacy Clinical Trial manuscript (Nature Communications; 2025) provided as supplementary information.

创建时间：

2025-07-04

Safety and Immunogenicity of a Live Attenuated RSV Vaccine in Healthy RSV-Seronegative Children 5 to 24 Months of Age

RSV疫苗临床试验

儿科疫苗免疫原性评估

Despite substantial morbidity associated with respiratory syncytial virus (RSV) infection, there is no licensed vaccine. MEDI-559 is a live attenuated intranasal vaccine candidate being developed for

Figshare2016-01-18 更新20

Table1_Efficacy and safety of respiratory syncytial virus vaccination during pregnancy to prevent lower respiratory tract illness in newborns and infants: a systematic review and meta-analysis of randomized controlled trials.docx

免疫接种策略

RSV疫苗临床试验

To evaluate the effectiveness and safety of respiratory syncytial virus (RSV) vaccination during pregnancy in preventing lower respiratory tract infection (LRTI) in infants and neonates, we conducted

NIAID Data Ecosystem00

Dataset from A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older

RSV疫苗临床试验

老年人群免疫

The purpose of this study for:Cohort 1 and Cohort 2: to assess the safety and reactogenicity of the intramuscular one- and two-dose regimens, with a booster at Month 12 (Cohort 1) and to select a regi

NIAID Data Ecosystem00

Dataset from A Phase 3, Observer-blind, Randomized, Placebo-controlled Study to Evaluate the Non-inferiority of the Immune Response and Safety of the RSVPreF3 OA Investigational Vaccine in Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults ≥60 Years of Age

RSV疫苗临床试验

呼吸道疾病免疫

The aim of this study is to demonstrate the non-inferiority (NI) of the immune response and evaluate safety of RSVPreF3 older adults (OA) investigational vaccine in adults 50-59 years of age (YOA), in

NIAID Data Ecosystem00

Dataset from A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Immunogenicity of an Ad26.RSV.preF-based Vaccine in Adults Aged 18 to 59 Years, Including Those at High-risk for Severe RSV

RSV疫苗临床试验

免疫原性评估

The purpose of the study is to investigate the safety and immunogenicity of the Ad26.RSV.preF based vaccine in adults 18 to 59 years of age who are healthy or at risk for severe Respiratory Syncytial

NIAID Data Ecosystem00

Immune Correlates Analysis of mRNA-1345 RSV Vaccine Efficacy Clinical Trial

资源简介：

相关数据集